Cargando…

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics

Highlights This study demonstrates that initiation of glucagon‐like peptide‐1 receptor agonists among individuals with type 2 diabetes (T2D), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), has remained low in the United States between 2014 and 2019, despite clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lingvay, Ildiko, Aroda, Vanita R., Honoré, Julie Broe, Ersbøll, Anne S., Nystrup Husemoen, Lise Lotte, Jensen, Anders Boeck, Sommer Matthiessen, Kasper, Kosiborod, Mikhail Naum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2023
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934953/ https://www.ncbi.nlm.nih.gov/pubmed/36796312 http://dx.doi.org/10.1111/1753-0407.13363

Ejemplares similares

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
por: Almandoz, Jaime P., et al.
Publicado: (2020)

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
por: Horowitz, Michael, et al.
Publicado: (2017)

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
por: Aroda, Vanita R., et al.
Publicado: (2018)

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021)

Lifestyle-Related Factors and Atopy in Seven Danish Population-Based Studies from Different Time Periods
por: Skaaby, Tea, et al.
Publicado: (2015)

IgE sensitization to inhalant allergens and the risk of airway infection and disease: A population-based study
por: Skaaby, Tea, et al.
Publicado: (2017)

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK
por: Husemoen, Lise Lotte Nystrup, et al.
Publicado: (2021)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Vitamin D Status and Cause-Specific Mortality: A General Population Study
por: Skaaby, Tea, et al.
Publicado: (2012)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Vitamin D Status and Chronic Obstructive Pulmonary Disease: A Prospective General Population Study
por: Skaaby, Tea, et al.
Publicado: (2014)

An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
por: Rameshrad, Maryam, et al.
Publicado: (2020)

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis
por: Rayner, Christopher K., et al.
Publicado: (2020)

Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
por: Bensignor, Megan O., et al.
Publicado: (2022)

Cause-Specific Mortality According to Urine Albumin Creatinine Ratio in the General Population
por: Skaaby, Tea, et al.
Publicado: (2014)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening
por: Rosenstock, Julio, et al.
Publicado: (2021)

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial
por: Del Prato, Stefano, et al.
Publicado: (2020)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
por: Edwards, Khary, et al.
Publicado: (2023)

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom
por: Feher, Michael, et al.
Publicado: (2017)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
por: Simonsen, Lotte, et al.
Publicado: (2022)

Metformin and Type 2 Diabetes Prevention
por: Aroda, Vanita R., et al.
Publicado: (2018)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
por: Yassin, Sayf A, et al.
Publicado: (2017)

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment
por: Aroda, Vanita R., et al.
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes
por: Valensi, Paul, et al.
Publicado: (2017)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_084l4dlo49ldh8rcctavsr7fq7